Long Focus Capital Management LLC Cuts Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Long Focus Capital Management LLC significantly reduced its holdings in BioNTech, selling 751,000 shares and bringing its total ownership down by 82.5% during the first quarter.
• Analysts have mostly maintained a positive outlook, with several firms upgrading their price targets for BioNTech; notably, Bank of America raised its target from $126.00 to $134.00.
• BioNTech reported earnings of ($1.60) EPS for the quarter, missing expectations but achieving a revenue increase of 102.6% year-over-year, resulting in total revenue of $306.46 million.

Long Focus Capital Management LLC trimmed its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 82.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,000 shares of the company's stock after selling 751,000 shares during the quarter. Long Focus Capital Management LLC owned 0.07% of BioNTech worth $14,479,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise purchased a new position in BioNTech during the 1st quarter worth $36,000. Costello Asset Management INC purchased a new position in BioNTech during the 1st quarter worth $91,000. Goodman Advisory Group LLC purchased a new position in BioNTech during the 1st quarter worth $105,000. Whittier Trust Co. grew its stake in BioNTech by 3,846.2% during the 1st quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after buying an additional 2,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in BioNTech by 61.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after buying an additional 713 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright dropped their target price on BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Morgan Stanley boosted their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Bank of America boosted their price target on BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Truist Financial reiterated a "buy" rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. dropped their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Price Performance

NASDAQ BNTX traded down $0.20 during trading hours on Wednesday, reaching $100.42. The company's stock had a trading volume of 530,359 shares, compared to its average volume of 925,894. The firm has a market capitalization of $24.14 billion, a price-to-earnings ratio of -62.76 and a beta of 1.39. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The company's 50-day moving average is $109.51 and its two-hundred day moving average is $104.74.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.